Phase 2 Study of DKN-01 in Colorectal Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This is a Phase 2 randomized, open-label, two-part, multicenter study with a safety run-in to evaluate efficacy and safety of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus standard of care (SOC) \[FOLFIRI/FOLFOX and bevacizumab\] as second-line treatment of advanced CRC patients.
Epistemonikos ID: fcf552ab5eb4422c33aee98b6c6e2a3c9e60d273
First added on: May 13, 2024